Taro Pharmaceuticals U.s.a., Inc.

Taro Pharmaceuticals U.s.a., Inc. (United States) is linked to 1 FDA-registered manufacturing site. 44 FDA enforcement records are linked to it.

Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records

Cite as: PharmaTek, “Taro Pharmaceuticals U.s.a., Inc.: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/taro-pharmaceuticals-u-s-a-inc

Overview

Taro Pharmaceuticals U.s.a., Inc. is a pharmaceutical company headquartered in Hawthorne, United States.

Registered manufacturing sites (1)

Physical sites registered with the US FDA and resolved to Taro Pharmaceuticals U.s.a., Inc., with any EU/UK GMP documents matched to each site. Headquarters and manufacturing locations can differ.

FDA compliance signals

44 FDA enforcement records linked to this company.

  • recall — Class III2024-08-21

    Failed Impurities/Degradation Specifications: Out-of-specification results obtained for related impurities and slightly lower than the established level of the Hydrocortisone Assay obtained during stability testing.

  • recall — Class III2022-04-06

    Failed Content Uniformity Specifications: Out-of-specification result for the Betamethasone Dipropionate assay of a stability sample

  • recall — Class I2022-01-19

    Microbial Contamination of Non-Sterile Products: presence of R. Pickettii bacteria

  • recall — Class II2021-02-10

    CGMP deviations.

  • recall — Class II2020-12-23

    Failed Impurities/Degradation Specifications: An unknown degradation impurity was detected slightly above the specification limit in Clotrimazole Cream USP 1%.

  • recall — Class II2020-12-23

    Failed Impurities/Degradation Specifications: An unknown degradation impurity was detected slightly above the specification limit in Clotrimazole Cream USP 1%.

  • recall — Class II2020-12-23

    Failed Impurities/Degradation Specifications: An unknown degradation impurity was detected slightly above the specification limit in Clotrimazole Cream USP 1%.

  • recall — Class II2020-12-23

    Failed Impurities/Degradation Specifications: An unknown degradation impurity was detected slightly above the specification limit in Clotrimazole Cream USP 1%.

  • recall — Class II2020-12-23

    Failed Impurities/Degradation Specifications: An unknown degradation impurity was detected slightly above the specification limit in Clotrimazole Cream USP 1%.

  • recall — Class II2020-12-23

    Failed Impurities/Degradation Specifications: An unknown degradation impurity was detected slightly above the specification limit in Clotrimazole Cream USP 1%.

  • recall — Class II2020-12-23

    Failed Impurities/Degradation Specifications: An unknown degradation impurity was detected slightly above the specification limit in Clotrimazole Cream USP 1%.

  • recall — Class II2020-12-23

    Failed Impurities/Degradation Specifications: An unknown degradation impurity was detected slightly above the specification limit in Clotrimazole Cream USP 1%.

  • recall — Class II2020-12-23

    Failed Impurities/Degradation Specifications: An unknown degradation impurity was detected slightly above the specification limit in Clotrimazole Cream USP 1%.

  • recall — Class II2020-12-23

    Failed Impurities/Degradation Specifications: An unknown degradation impurity was detected slightly above the specification limit in Clotrimazole Cream USP 1%.

  • recall — Class III2020-08-19

    Failed Content Uniformity: bulk lot used to make these two lots was found to have failed content uniformity.

  • recall — Class I2020-03-04

    Resuspension Problems: Two lots of Phenytoin Oral Suspension USP 125mg/5mL may coagulate and may not resuspend as per the label copy instructions.

  • recall — Class I2020-02-19

    Cross Contamination; Lamotrigine Tablets 100 mg USP was contaminated with enalapril maleate.

  • recall — Class II2019-11-06

    Presence of Foreign Substance: Ibuprofen Oral Suspension USP may have small particles of an inert plastic material introduced during manufacturing.

  • recall — Class II2019-11-06

    Presence of Foreign Substance: Ibuprofen Oral Suspension USP may have small particles of an inert plastic material introduced during manufacturing.

  • recall — Class II2019-11-06

    Presence of Foreign Substance: Ibuprofen Oral Suspension USP may have small particles of an inert plastic material introduced during manufacturing.

  • recall — Class II2019-11-06

    Presence of Foreign Substance: Ibuprofen Oral Suspension USP may have small particles of an inert plastic material introduced during manufacturing.

  • recall — Class II2019-11-06

    Presence of Foreign Substance: Ibuprofen Oral Suspension USP may have small particles of an inert plastic material introduced during manufacturing.

  • recall — Class II2018-11-21

    Failed Impurities/Degradation Specifications: unknown impurity higher than the specified limit was detected during routine stability testing.

  • recall — Class II2018-11-21

    Failed Impurities/Degradation Specifications: unknown impurity higher than the specified limit was detected during routine stability testing.

  • recall — Class II2018-11-21

    Failed Impurities/Degradation Specifications: unknown impurity higher than the specified limit was detected during routine stability testing.

  • recall — Class III2018-02-07

    Failed Content Uniformity Specifications

  • recall — Class III2017-11-01

    Cross contamination with other products: traces of Dapsone were found in the finished product.

  • recall — Class III2017-05-24

    Cross contamination with other products: Certain lots of Fluocinonide Cream were found to be contaminated with a small quantity of hydrocortisone-17-valerate.

  • recall — Class II2017-04-26

    Failed Content Uniformity Specifications; out-of-specification (OOS) results 18-month stability

  • recall — Class III2016-11-16

    Subpotent Drug: Out of Specification assay values on stability for the active ingredient, zinc pyrithione.

  • recall — Class III2016-06-08

    Subpotent Drug

  • recall — Class II2015-02-11

    Presence of Foreign Substance: Presence of blue plastic floating in loratadine syrup.

  • recall — Class III2014-11-05

    Marketed without an Approved NDA/ANDA: One lot was on hold-pending release status when it was erroneously made available for sale in the inventory control system. An alternate manufacturing site for the Carbamazepine API final intermediate was pending approval.

  • recall — Class III2014-09-24

    Failed Content Uniformity Specifications.

  • recall — Class III2013-12-18

    Subpotent. drug

  • 4832013-04-18

    Complaint Handling Procedure

  • 4832013-04-18

    Failure to develop written procedures

  • 4832013-04-18

    Failure by applicant to report ADE

  • recall — Class II2012-12-12

    Product Lacks Stability: Out-of-specification (OOS) results were observed for assay and description in retain samples.

  • 4832012-03-08

    Late submission of 15-day report

  • 4832012-03-08

    Wrong form - domestic ADE

  • 4832009-05-29

    Failure to review ADE information

  • 4832009-05-29

    Late submission of quarterly safety reports

  • 4832009-05-29

    Late submission of 15-day report

For suppliers

Is this Taro Pharmaceuticals U.s.a., Inc.?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.

Need suppliers found and checked?

The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.